CRNO-B.ST Cereno Scientific AB Series B

Healthcare Biotechnology Stockholm Exchange
1.64 SEK
Close of Nov 5, 2026
1.53 8.92
Market cap
SEK 529M
P/E
-
P/B
2.30x
ROE
-50.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CRNO-B.ST undervalued?

Graham number

The Graham number of Cereno Scientific AB Series B cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Cereno Scientific AB Series B fundamental analysis

No fundamental analysis for Cereno Scientific AB Series B yet.

Cereno Scientific AB Series B stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Cereno Scientific AB Series B

Cereno Scientific AB (publ), a clinical stage biotechnology company, develops therapeutics to treat cardiovascular and pulmonary diseases in Sweden. The company's lead drug candidate is CS1, a HDACi, proprietary reformulation of VPA that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an epigenetic modulator for pathological vascular remodeling, fibrotic tissue rem…

Full company profile